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Abstract
The success of coronary artery bypass grafting (CABG) is limited by poor long-term graft patency.
Saphenous vein is used in the vast majority of CABG operations, although 15% are occluded at one
year with as many as 50% occluded at 10 years due to progressive graft atherosclerosis.
Intravascular ultrasound (IVUS) has greatly increased our understanding of this process. IVUS
studies have shown that early wall thickening and adaptive remodeling of vein grafts occurs within
the first few weeks post implantation, with these changes stabilising in angiographically normal vein
grafts after six months. Early changes predispose to later atherosclerosis with occlusive plaque
detectable in vein grafts within the first year. Both expansive and constrictive remodelling is present
in diseased vein grafts, where the latter contributes significantly to occlusive disease. These findings
correlate closely with experimental and clinicopathological studies and help define the windows for
prevention, intervention or plaque stabilisation strategies. IVUS is also the natural tool for
evaluating the effectiveness of pharmacological and other treatments that may prevent or slow the
progression of vein graft disease in clinical trials.
Introduction
The success of coronary artery bypass grafting (CABG),
although the gold standard for the treatment of multives-
sel coronary artery disease, is limited by poor long-term
vein graft patency [1]. Early vein graft thrombosis (within
1 month) occurs in up to 15% of vein grafts due to graft
spasm or technical error [2,3], whilst late vein graft failure
occurs as a consequence of early neointimal hyperplasia
with later superimposed atheroma, so called 'vein graft
disease' [1,4] and as many as 50% of all vein grafts are
occluded at 10 years post surgery [5,6]. Despite the supe-
riority of arterial graft patency over that of vein grafts, the
multivessel nature of coronary artery disease and ready
availability of saphenous vein still result in its use in over
70% of CABG procedures [7]. The alternative treatment
modality for multivessel coronary atheroma, percutane-
ous coronary artery angioplasty and stenting (PCI), has
traditionally suffered from even worse long-term results
compared to CABG, due to high early restenosis rates;
over 30% within 1 year [8]. This results in more frequent
and more rapid return of symptoms and major adverse
cardiac events (MACE) with PCI compared to CABG,
necessitating more repeat revascularisation procedures
[8]. The apparent success of new drug eluting stents has
challenged this paradigm however. Rapamycin (a mac-
rolide antibiotic) and the taxane, paclitaxel, two agents
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with potent antiproliferative properties, eluted from intra-
coronary stents, have dramatically reduced restenosis
rates, MACE and reintervention rates in clinical trials
[9,10], to the point where the superiority of CABG is now
being seriously challenged [11]. This represents the clini-
cal application of intensive research into the mechanisms
of atherosclerosis and restenosis and strategies for their
prevention over the last decade. Conversely, CABG has
suffered from its apparent success, and with some excep-
tions [12], there have been comparatively few attempts to
prevent or inhibit the progression of vein graft disease in
CABG patients, a condition that must change. Vein graft
disease differs from arterial atherosclerosis in that its nat-
ural history is much shorter and the date of onset is clearly
defined, i.e. graft implantation. This process is therefore
potentially amenable to strategies that may inhibit its
progression.
Although the cellular and molecular mechanisms under-
lying vein graft disease have been systematically investi-
gated, the time course and development of this process in
patients after coronary bypass has only recently been
defined as a consequence of the increasing use of intravas-
cular ultrasound (IVUS). Quantitative coronary angiogra-
phy, traditionally the predominant imaging modality
used to assess the severity of vein graft disease underesti-
mates the severity of vein graft remodeling and ather-
manous plaque development by measuring the vessel
lumen in only two dimensions [13,14]. In contrast, the
tomographic IVUS image enables visualization of the full
circumference of the vessel wall [15] allowing measure-
ment of wall thickening, vein remodeling and atheroscle-
rotic plaque size, distribution, and composition [15]. This
results in the detection of diffuse atherosclerotic plaque,
compensatory vessel enlargement and preservation of the
luminal diameter even in angiographically normal vessels
[13,14,16]. IVUS findings in vein grafts also show good
correlation with histological findings in clinicopathologi-
cal studies [17]. The purpose of this review is to summa-
rize our current understanding of the natural history of
vein graft disease from IVUS studies, correlate this with
the findings of experimental and clinicopathological stud-
ies, and, finally to consider how this knowledge, may be
used to target prevention or treatment strategies.
Early changes in saphenous vein bypass grafts; wall 
thickening and adaptive remodelling
Glagovian remodeling was first described as a radial
enlargement of the entire cross sectional area of a vessel in
response to intramural atheroma [18]. First identified in
humans in post-mortem studies it was only with the wide-
spread use of IVUS that its central role in atherosclerosis,
post angioplasty restenosis, transplant vasculopathy and
vein graft disease was realised [15]. Currently, the term
not only applies to vessel enlargement, but also shrinkage,
where in the presence of underlying plaque it becomes an
important determinant of lumen loss [19]. In vein grafts,
early after implantation, increases in overall vessel cross
sectional area preserve luminal size despite significant
increases in wall thickness [16]. IVUS measured parame-
ters of vessel remodeling and wall thickening in vein grafts
pre, or early post implantation versus later periods are
described in Table 1. Vein graft dimensions within one
month of implantation are remarkably similar to those in
grafts prior to implantation [16,20,24], with significant
wall thickening having occurred by six months, even in
angiographically normal grafts [14,16]. Other studies
have demonstrated wall thickening as early as 3 weeks to
3 months after CABG [23,24]. These changes are diffuse
and concentric, and are observed from the aortic root to
the coronary anastomosis [23,24]. Higuchi and colleagues
compared IVUS measurements of 15 vein grafts per-
formed within 1 month postoperatively with 14 vein
grafts after 6 months postoperatively. This showed that
significant wall thickening had occurred by 6-months,
accompanied by compensatory enlargement, and preser-
vation of the graft luminal diameter (Table 1), however
wall thickening appeared to reach a plateau after 6
months with preservation of lumen area (Figure 1), sug-
gesting that early remodeling responses may stabilize in
the absence of atherosclerotic development [16].
IVUS changes correlate closely with the findings of exper-
imental and clinical studies. In porcine saphenous vein
Increases in wall thickness versus time after surgery Figure 1
Increases in wall thickness versus time after surgery. Wall 
area expressed as a percentage of total vessel area (%VWA) 
exceeded 40% and reached a plateau state after 6 months in 
angiographically normal vessels. Reproduced with permission 
from Higuchi et al, Heart Vessels 2002, 17:57–60, Springer – 
Verlag, Heidelberg, Germany [16].Cardiovascular Ultrasound 2004, 2:8 http://www.cardiovascularultrasound.com/content/2/1/8
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bypass grafts, in the first week after grafting, adventitial
medial and neointimal thickening occurs as a conse-
quence of increased shear stress, surgical preparative
injury and the subsequent activation of multiple growth
factor and cytokine cascades. This is associated with the
infiltration of inflammatory cells, medial smooth muscle
cell proliferation and migration to form a neointima [25].
Adventitial myofibroblast proliferation and extracellular
matrix deposition also results in the formation of a thick
neoadventitia [26]. These myofibroblasts migrate through
all the layers of the vessel wall, where subsequent extracel-
lular matrix deposition contributes to overall wall thick-
ening [27]. A similar distribution of cytoskeletal proteins
characteristic of myofibroblasts is observed in explanted
human saphenous vein grafts suggesting that similar
mechanisms occur in man [27]. After the first week, wall
thickening in porcine vein grafts occurs largely due to
extracellular matrix deposition (fibrosis) and neointimal
smooth muscle cell proliferation, however this thickening
plateaus after one month [26].
The early changes seen in the vessel wall of vein grafts are
similar to those seen during vessel remodeling in athero-
sclerotic coronary artery segments [19]. In normal arteries,
remodeling is a homeostatic response to changes in flow
and circumferential stretch, with compensatory
enlargement and wall thickening normalizing shear stress
and wall tension in response to higher blood pressures
and flow velocities respectively. Outward remodeling in
response to increased flow is largely dependent on shear-
responsive endothelial production of nitric oxide and the
gelatinase matrix metalloproteinases (MMPs) MMP-2 and
MMP-9 [28,29]. MMPs are central to the turnover of the
extracellular matrix, altering cell-cell interactions, modify-
ing the extracellular milieu and permitting the movement
and division of cells. Increased MMP production, with
extracellular matrix degradation is a feature of the infiltra-
tion of inflammatory cells as well as the migration of
smooth muscle cells and myofibroblasts [30,31], and this
may also contribute to the remodeling process [19].
Late changes in vein grafts: atherosclerosis and 
pathological remodelling
Early vein graft changes can be viewed as adaptive, how-
ever they also predispose the graft to later accelerated graft
atherosclerosis [32]. Several components of the extracellu-
lar matrix that are abundant in diffuse fibrous intimal
hyperplasia may increase the residence of atherogenic
molecules, and promote the development of lipid-laden
lesions [33,34]. Similarly, myofibroblasts are associated
with contractile responses as part of wound healing [35]
and it has been hypothesized that dissemination of these
cells throughout all layers of the vein graft may be central
to later inadequate or constrictive vessel remodeling
[36,37].
Risk factors for, and the microscopic appearance of vein
graft atherosclerosis are largely similar to those in coro-
nary arteries and it is reasonable to suggest that similar
pathological mechanisms are at work, however these
occur over a much more rapid time course in vein grafts
[1,4]. Atheromatous plaque is detected by IVUS as early as
eight to ten months post grafting [38] in association with
both expansive and constrictive remodelling [22] (Table
2). This is much earlier than originally suggested by angi-
ography [5,6]. Early IVUS studies disagreed as to the
nature of vein graft remodeling, with some studies report-
ing expansive remodeling [21,38] whilst others did not
Table 1: Early adaptive changes and neointima formation in saphenous vein grafts
Study 
Reference
Grafts / 
Patients
Pre implantation to 1 month 
(mm2)
>12 months (mm2)
Lumen Wall 
Area
Vessel 
CSA
%wall 
area
Lumen Plaque 
area
Wall Area EEL area Vessel CSA % plaque 
area
%wall 
area
Nishioka 
et al 1996 
[20]
43/42 16.5 ± 5.7 7.4 ± 2.1 23.9 ± 7.3 32.3 ± 7 8.9 ± 2.7 10.0 ± 5.3 15.2 ± 5.8 18.8 ± 7.5 24.0 ± 7.8 51 ± 10 63 ± 7
Ge et al 
1999** 
[21]
43/43 12.6 ± 4.0 – 
19.0 ± 9.7
64.5 ± 15.5
Hong et al 
1999** 
[22]
104/93 12.0 ± 4.2 – 
3.8 ± 1.9
7.2 ± 4.1 – 
13.9 ± 4.9
10.0 ± 3.0 – 
20.3 ± 6.5
16.7 ± .9 
17.8 ± 6.1
20.8 ± 5.1 – 
24.1 ± 7.8
30 ± 5 – 
79 ± 9
45 ± 5 – 
83 ± 7
Higuchi et 
al 2002τ 
[16]
47 16.2 ± 5.5 5.3 ± 2.0 21.6 ± 7.1 24.9 ± 5.0 12.8 ± 4.6 15.8 ± 5.2 28.8 ± 8.8 55.7 ± 6.8
**values represent range from reference segment to focal stenosis, τ angiographically normal vein. Vessel CSA, (cross sectional area) measured by 
tracing the outer border of the whole vein graft, Wall area, Vessel CSA minus lumen area. Percent wall area was calculated as the wall area divided by 
Vessel CSA. In situ veins do not have an external elastic membrane however; arterialized saphenous vein grafts develop a sonolucent zone, which has 
been reported to represent media. The EEL (external elastic membrane) area is measured by tracing the outer border of this sonolucent zone. Plaque 
area is calculated as external elastic membrane minus lumen area. Percent plaque area is calculated as plaque area divided by external elastic 
membrane area; this has also been called the plaque burden. Plaque burden and percent wall are closely correlated.Cardiovascular Ultrasound 2004, 2:8 http://www.cardiovascularultrasound.com/content/2/1/8
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[20]. This confusion was most likely due to the small sam-
ple sizes in these early studies however (Table 2). Hong et
al [22] used IVUS to assess the extent and direction of
remodeling in 104 grafts in 93 patients, the largest analy-
sis of diseased vein grafts published to date. In individual
lesions, they defined remodeling by comparing the area
within the EEL at the site of stenosis to that of a reference
point. Positive remodeling was defined as a stenosis/ ref-
erence EEL area ratio >1.1, intermediate remodeling as a
ratio 0.9 to 1.1, and negative remodeling as a ratio <0.9
[39]. All three processes were shown to occur, sometimes
even within the same vessel. Overall plaque burden was
greater in positively remodeled segments compared with
intermediate or negative remodeling, whilst lumen area
was preserved in all groups [22]. This is similar to changes
that occur in atherosclerotic coronary arteries [40]. Men-
dellson and colleagues identified expansive remodeling in
98.5% of 24 vein graft lesions studied (Table 2). They
showed that lumen area did not change with increasing
percent area stenosis for vessels with ~30% of their area
occupied by plaque (p = NS), however, for segments with
>30% of the vessel area occupied by plaque, there was an
inverse relation with the lumen area [38]. In this group
(with >30% effective plaque area stenosis), the lumen
area decreased as the percentage of vessel area occupied by
plaque increased. Again these were the same changes as
those noted in coronary arteries [41]. They suggest that
"compensatory" enlargement mechanisms are very effec-
tive for early atherosclerotic lesions; but as lesions become
more progressive, these mechanisms can no longer com-
pensate, and lumen narrowing occurs. This does not
explain constrictive or negative remodeling however and
the mechanisms underlying this process remain unclear.
In addition to the role of myofibroblasts, the formation of
a dense neoadventitia with extensive collagen deposition
has been implicated as a mechanical barrier to vessel
enlargement, with later remodeling of this fibrous tissue
ultimately resulting in vessel shrinkage [37]. In atheroscle-
rotic arteries negative or inadequate remodeling is more
common in insulin-using than non-insulin-using diabet-
ics [42], more common in smokers compared with non-
smokers, and less frequent in patients with
hypercholesterolaemia [43]. Mendellson et al showed
that expansive vein graft remodeling was independent of
graft age, insertion site, plaque eccentricity, patient age, or
gender [38]. Altered local haemodynamics can also affect
remodeling. Low shear predisposes the inner curves of tor-
tuous segments to develop atheroma and may impair
outward remodeling in a similar manner [44,45]. Alterna-
tively, medial thinning as a consequence of atheroscle-
rotic plaque development may result in bulging of the
vessel wall due to diminished structural support at the site
of the plaque [46]. Plaque volume often correlates with
the level of inflammatory infiltrate, which again may con-
tribute to expansion by promoting collagen lysis and dep-
osition of loose myxoid extracellular matrix [47]. This is
thought to underlie the propensity for such plaques to
rupture and explain the association between expansive
remodeling and unstable coronary symptoms [19].
The future
IVUS studies have clearly shown that early 'adaptive' or
pathological changes occur within weeks of grafting and
that occlusive atheroma, in susceptible individuals occurs
within 1 year. IVUS studies have therefore defined the
window in which strategies to inhibit vein graft disease
Table 2: Late remodeling in atherosclerotic vein grafts
Grafts /
Patients
Latency
(years)
Lumen area Intimal and 
medial(plaque)
area
External elastic lamina 
area
Reference Stenosis Reference Stenosis Reference Stenosis
Mendellson 
et al 1995 
[38]
21/19 0.8–16 14.6 ± 7.5 7.1 ± 4.5 5.6 ± 3.4 18.3 ± 7.0 20.2 ± 8.5 25.4 ± 8.2
Nishioha et 
al 1996 [20]
43/42 3–12 15.7 ± 6.8 5.0 ± 1.5 3.2 ± 1.5 13.7 ± 6.3 18.9 ± 7.0 18.7 ± 7.3
Ge et al 
1997 [21]
43/43 1–6 12.6 ± 4.0 19.0 ± 9.7
Hong et al 
1999 [22]
Negative 
remodeling
104/93 1.2–20.7 12.5 ± 4.0 3.6 ± 2.0 5.0 ± 2.4 - 10.9 ± 6.2 17.8 ± 7.9 14.2 ± 8.1
Positive 
remodeling
11.8 ± 3.5 4.0 ± 1.8 5.1 ± 1.4 15.3 ± 4.7 16.7 ± 4.6 19.4 ± 6.2
Remodeling can be defined as the ratio of the EEL at the site of the stenosis to that of the reference point. Positive remodeling is defined as a 
stenosis/ reference EEL area ratio >1.1, intermediate remodeling is defined as a ratio 0.9 to 1.1, and negative remodeling as a ratio <0.9.Cardiovascular Ultrasound 2004, 2:8 http://www.cardiovascularultrasound.com/content/2/1/8
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might be effective. Furthermore, in addition to its advan-
tages over coronary angiography, IVUS in vein grafts has
been shown to be both accurate [12,16] and reproducible
[20,22] making it the obvious investigational tool to
explore the effectiveness of these strategies on in clinical
trials. IVUS measurements correlate closely with clinico-
pathological findings [12] and can detect standardised
differences of >1 in studies of saphenous vein grafts versus
ungrafted vein as well as in vein grafts early post implan-
tation (within 1 month) compared with later periods
[16,20]. In addition, Nishioka and colleagues [20] dem-
onstrated that for the measurement of lumen area, the
mean difference between two observations by the same
observer was 3.1%, with a range of 0% to 9.0%. Between
two observers, the mean difference was 3.8%, with a range
of 1.0% to 5.6%. This reproducibility facilitates not only
accurate comparisons between groups of patients but also
assessment of the effects of intervention on grafts in lon-
gitudinal studies.
The ability to manipulate vein grafts ex vivo prior to
implantation using pharmacological or other methods
that may inhibit subsequent disease is a feature unique to
vein graft disease. There are many examples of this being
successfully achieved in experimental models. Pre-treat-
ment with rapamycin [48], paclitaxel (GD Angelini,
unpublished observations) and the intracellular calcium
dependant ATPase inhibitor, thapsigargin [4], have been
shown to significantly inhibit the progression of vein graft
disease in experimental models in vivo. Oral agents, such
as NO donating aspirins [49] and endothelin antagonists
have also been shown to be effective in porcine vein grafts
in vivo [50] as has the application of a porous external
polyester stent which inhibits neointima formation and
promotes expansive remodelling in the absence of vein
wall thickening [51]. Targeted gene transfer is another
attractive option, with viral transfer of E2F-decoy oligonu-
cleotides inhibiting vein graft failure after peripheral arte-
rial reconstruction in clinical trials [52]. Stabilisation of
vein grafts that have undergone early adaptive changes,
but have yet to develop a large plaque burden is also a
possibility. Risk factor modification such as cessation of
smoking and aggressive lipid lowering [62–64] has been
shown to improve long-term graft patency on angiogra-
phy. The effect of other interventions such as antiplatelet
therapy on the progression of vein graft disease have not
been evaluated in IVUS studies however. Identification of
patients with a large plaque burden on IVUS, but other-
wise angiographically normal vein grafts may also enable
targeted plaque stabilisation therapy.
Conclusion
IVUS has significantly contributed to our understanding
of vein graft failure. It also serves as the natural tool for the
development of clinical strategies that may lead to signif-
icant improvements in vein graft patency and more
importantly for better long-term quality of life and lon-
gevity for patients with coronary artery disease. The intro-
duction of clinical trials to address this Achille's heel of
coronary bypass surgery are long overdue.
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